Insmed, Inc. (INSM) Financials
Key financial figures for Insmed, Inc. (Q3 2026).
Insmed Q3 revenue of $524.4M (BRINSUPRI $400.1M, ARIKAYCE $124.4M) beat the FMP estimate; both products' 2026 guidance low ends raised. Total revenue $524.4M vs $142.3M a year earlier, about 4.8% above the FMP estimate of $500.4M. BRINSUPRI revenue $400.1M, up 29% from Q2 ($309.2M); ARIKAYCE $124.4M, up 9% YoY (international +21%, U.S. +2%). Net loss $100.3M ($0.46 per share) vs $370.0M ($1.75) a year earlier; loss per share wider than the FMP estimate of about $0.38, and wider than Q2's $13.2M loss that a $99.8M non-cash gain had cushioned. 2026 guidance raised at the low end: BRINSUPRI $1.35B to $1.40B (from $1.25B to $1.40B), ARIKAYCE $460M to $470M (from $450M to $470M). On the outlook: 2026 revenue guidance raised at the low end: BRINSUPRI $1.35 billion to $1.4 billion (previously $1.25 billion to $1.4 billion); ARIKAYCE $460 million to $470 million (previously $450 million to $470 million). Peak revenue estimates unchanged: BRINSUPRI more than $7 billion, TPIP more than $6 billion, ARIKAYCE more than $1 billion. Figures are for Q3 2026, as Insmed Incorporated reported them.
- Revenue
- $524M
- Net Income
- -$100M
- EPS
- $-0.46
- Total Assets
- $2.2B
- Operating Cash Flow
- -$36M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $524M | -$100M | -$0.46 | -17.04% | -$42M |
| Q2 FY2026 | $425M | -$13M | -$0.06 | -0.36% | -$95M |
| Q1 FY2026 | $306M | -$164M | -$0.76 | -65.46% | -$226M |
| Q4 FY2025 | $264M | -$328M | -$1.54 | -94.64% | -$294M |
| Q3 FY2025 | $142M | -$370M | -$1.75 | -257.13% | -$222M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $606M | -$1.3B | -$6.42 | -194.04% | -$968M |
| FY2024 | $364M | -$914M | -$5.57 | -241.47% | -$706M |
| FY2023 | $305M | -$750M | -$5.34 | -232.51% | -$550M |
Frequently asked questions
What was Insmed Incorporated's revenue last quarter?
Insmed Incorporated reported revenue of $524.4 million for Q3 FY2026, up 268.4% from the same period a year earlier.
Is Insmed Incorporated profitable?
Not in its most recent reported period. Insmed Incorporated reported a net loss of $100.3 million for Q3 FY2026, a net margin of -19.13% on revenue.
How has Insmed Incorporated's margin trended?
Operating margin was -17.04% in Q3 FY2026, compared with -257.13% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Insmed Incorporated generate?
Insmed Incorporated generated free cash flow of -$42.1 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Insmed, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.